Filter posts

Will the PTAB Be A Roadblock for Biotech? Stories from Sessions at BIO 2016

We’re at the beginning of day 3 here at BIO 2016, and that means we’ve already had …

IP Sessions at BIO 2016--Come Join us in San Francisco!

That’s right, we’re back at it again! This year’s BIO International Convention will host several innovative …

Join us for the IP Symposium at the 2016 BIO World Congress!

Ah, San Diego. What is it they say about you? Come for the beaches…. Stay …

What We’ll Be Talking about at the BIO Spring IPCC Conference

It’s time once again for BIO’s Spring IPCC Conference! BIO’s biannual Intellectual Property Counsels Committee …

"II Ca-Be-lly, or Not II Ca-Be-lly?”: Is The Famous Cabilly II Antibody Patent Near Extinction?

Guest post by Konstantin Linnik, Ph.D., Isaac Hubner, Ph.D, and Lana Gladstein, who are attorneys …

Patently Biotech’s Top Articles of 2015

Intellectual property and patent reform have dominated headlines in 2015. As we close out the …

Patent Reform in the News

The New York Post and The Washington Post have both run Op-eds in the last week addressing …

BIO on CNBC: IPR System Weakens Medical Innovation

Last night Ron Cohen, M.D., CEO of Acorda Therapeutics and BIO’s board chair, appeared on …

Here are the Facts about the IPR Kill Rate

FiercePhrma recently ran an article repeating a dubious analysis of the crisis caused by the …

102 Organizations Urge Congress to Maintain a Strong Patent System and Protect Innovation

A diverse group of more than 100 national and state-based advocacy organizations have united to …